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Purpose of the study
The orphan nuclear receptors PXR (pregnane × receptor)
and CAR (constitutive androstane receptor) are xenosen-
sors that mediate drug-induced transcription of genes
involved in drug metabolism, clearance and disposition.
Early studies indicate that ritonavir (RTV), saquinavir
(SQV) and efavirenz (EFV) modulate CYP3A4 expression
via PXR, albeit at non-clinical concentrations. However,
little information is available regarding newer antiretrovi-
ral agents or the effects on transcriptional regulation of
CYP2B6. This study investigates the role of PXR and CAR
in the transcriptional regulation of CYP3A4 and CYP2B6
by ART.
Methods
HepG2 cells were transfected with the nuclear receptor
plasmids, luciferase reporter gene constructs and an inter-
nal standard (pRL-TK), and incubated in medium supple-
mented with RTV, TFV (Tenofovir), NFV (Nelfinavir), IDV
(Indinavir), NVP (Nevirapine), SQV, EFV or FOS (Fosam-
prenavir) for 48 hrs. Rifampicin and CITCO were positive
controls. Transcriptional activation was measured using a
dual-luciferase reporter assay and data normalised to the
internal standard, and expressed relative to the untreated
controls.
Summary of results
The rank order for PXR-mediated transcriptional activa-
tion of CYP3A4 was FOS = LPV, > NFV = EFV> SQV (Table
1). None of these drugs altered CYP3A4 through a CAR
dependent mechanism. LPV strongly induced transcrip-
tional activation of CYP2B6 via PXR, while NFV, FOS, EFV
and RTV were weak activators (<3 fold). Only LPV and
NVP induced CAR-mediated activation of CYP2B6, albeit
weakly.
Conclusion
In conclusion, the results indicate that inductive effects of
PIs and NNRTIs on the CYP-P450 superfamily are due to
PXR rather than CAR regulatory mechanisms. Newer PIs
such as LPV and FOS are as likely to induce CYP3A4 and
2B6 expression by this pathway as older ARV agents and
may affect plasma levels of co-administered through
altered metabolism. Clinically relevant combinations and
all new drugs should be screened for PXR and CAR activa-
tion.
from Ninth International Congress on Drug Therapy in HIV Infection
Glasgow, UK. 9–13 November 2008
Published: 10 November 2008
Journal of the International AIDS Society 2008, 11(Suppl 1):P236 doi:10.1186/1758-2652-11-S1-P236
<supplement> <title> <p>Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection</p> </title> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1758-2652-11-S1-full.pdf">here</a>.</note> <url>http://www.biomedcentral.com/content/pdf/1758-2652-11-S1-info.pdf</url> </supplement>
This abstract is available from: http://www.jiasociety.org/content/11/S1/P236
© 2008 Svard et al; licensee BioMed Central Ltd. Page 1 of 2
(page number not for citation purposes)
Journal of the International AIDS Society 2008, 11(Suppl 1):P236 http://www.jiasociety.org/content/11/S1/P236Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright





Approx. Clinical Conc PXR/CYP3A4 CAR/CYP3A4 PXR/CYP2B6 CAR/CYP2B6
IDV (15 μM) 1.3 <1 1.5 <1
NFV (6 μM) 6.1 <1 3.0 <1
LPV (16 μM) 9.1 <1 8.6 1.6
RTV (1 μM) 1.9 <1 2.1 <1
TFV (1 μM) <1 1.2 ND ND
SQV (4 μM) 3.2 <1 ND ND
NVP (7.5 μM) <1 1.1 <1 1.6
EFV (10 μM) 5.8 <1 2.6 <1
FOS (13 μM) 10.4 1.4 2.9 1.3
Rifampicin (10 μM) 18.3 --- 15.9 ---
CITCO (100 nM) --- 3.4 --- 3.5Page 2 of 2
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